950601-82-8Relevant academic research and scientific papers
NOVEL COMPOUND HAVING ISOXAZOLE CORE AND PHARMACEUTICAL COMPOSITION FOR DIABETES CONTAINING THE SAME MOLECULAR SKELETONS
-
Paragraph 0107-0110, (2017/08/02)
The purpose of the present invention is to provide novel compounds having isoxazole by central structure as a PPAR gamma selective ligand, a manufacturing method thereof, and a pharmaceutical composition for treating PPAR gamma-related diseases containing the novel compounds or pharmaceutically acceptable salt thereof. The compounds can be applied to treatment of PPAR gamma-related diseases, especially, diabetes as an effective medicine without side effects which an existing TZD-series diabetes medicine has.
AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-α
-
Page/Page column 71, (2010/08/05)
Disclosed are compounds of the formula: (I) And pharmaceutically acceptable salts thereof, wherein the variables are as defined herein, which are useful in activating PP ARa and in treating atherosclerosis hypercholesterolemia, primary hypercholesterolemi
